Diseases · Entity Annotation Prototype (beta)

6articles mentioning diseases

13disease mentions

1distinct diseases extracted

0%of mentions human-reviewed

Active filtersEntity: SPMS ×

SPMS

This disease is selected. Its supporting articles are shown below.

SPMS6

Articles mentioning SPMS

6 articles · page 1 of 1

YI1 Disability trajectories of women with progressive multiple sclerosis phenotypes after pregnancy

bmjno · abstract · 2025-10-23 · 5 matching annotations

83.4%

multiple sclerosis SPMS

…ce of pregnancy on the disease course in women with progressive multiple sclerosis (MS) phenotypes has not been defined. The objective of this stu…

Autologous haematopoietic stem cell transplantation in multiple sclerosis: outcomes and predictors from German real-world data

jnnp · abstract · 2026-07-15 · 2 matching annotations

87.9%

multiple sclerosis MS RRMS SPMS PPMS aHSCT

…ion (aHSCT) represents a treatment option for highly aggressive multiple sclerosis (MS). Here, we report outcome analyses from the two largest Ger…

4CPS-162 Real-world evidence with ofatumumab in multiple sclerosis

ejhpharm · abstract · 2026-03-18 · 2 matching annotations

85.1%

multiple sclerosis MS SPMS RRMS ofatumumab ocrelizumab teriflunomide natalizumab

… all patients with relapsing-remitting or secondary progressive multiple sclerosis (RRMS; SPMS), who initiated Ofatumumab between January 2023 and…

168 Siponimod use in Northern Ireland

jnnp · abstract · 2025-11-26 · 2 matching annotations

83.2%

Secondary progressive MS SPMS Siponimod

…Secondary progressive MS (SPMS) currently has limited therapeutic options. Siponimod, a …

Tysabri Observational Program (TOP): long-term safety and effectiveness of natalizumab treatment in relapsing-remitting multiple sclerosis over 15 years

jnnp · abstract · 2026-06-12 · 1 matching annotations

84.5%

RRMS relapsing-remitting multiple sclerosis SPMS natalizumab natalizumab-associated NCT00493298 TOP

…tained real-world effectiveness of natalizumab in patients with RRMS ( NCT00493298).…

Blood biomarkers for predicting disability worsening in progressive multiple sclerosis: a multinational, individual participant-level analysis

jnnp · abstract · 2025-10-15 · 1 matching annotations

76.0%

multiple sclerosis MS pwPMS PMS pwSPMS SPMS BioMS-eu network centres dominant treatment

… (NfL) may help predict confirmed disability worsening (CDW) in multiple sclerosis (MS). However, data on the prognostic value of their blood conc…